DK3463457T3 - Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom - Google Patents
Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom Download PDFInfo
- Publication number
- DK3463457T3 DK3463457T3 DK17730627.1T DK17730627T DK3463457T3 DK 3463457 T3 DK3463457 T3 DK 3463457T3 DK 17730627 T DK17730627 T DK 17730627T DK 3463457 T3 DK3463457 T3 DK 3463457T3
- Authority
- DK
- Denmark
- Prior art keywords
- nivolumab
- blockade
- lymphoma
- refractory hodgkin
- hodgkin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344880P | 2016-06-02 | 2016-06-02 | |
| PCT/US2017/035492 WO2017210453A1 (en) | 2016-06-02 | 2017-06-01 | Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3463457T3 true DK3463457T3 (da) | 2023-10-02 |
Family
ID=59067911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17730627.1T DK3463457T3 (da) | 2016-06-02 | 2017-06-01 | Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11083790B2 (da) |
| EP (2) | EP4248990A3 (da) |
| JP (2) | JP7175198B2 (da) |
| KR (2) | KR20230038318A (da) |
| CN (1) | CN109475633A (da) |
| DK (1) | DK3463457T3 (da) |
| ES (1) | ES2954139T3 (da) |
| FI (1) | FI3463457T3 (da) |
| HR (1) | HRP20230864T1 (da) |
| HU (1) | HUE062398T2 (da) |
| LT (1) | LT3463457T (da) |
| PL (1) | PL3463457T3 (da) |
| PT (1) | PT3463457T (da) |
| RS (1) | RS64388B1 (da) |
| SI (1) | SI3463457T1 (da) |
| WO (1) | WO2017210453A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018000621A (es) | 2015-07-13 | 2018-05-11 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. |
| KR102055396B1 (ko) | 2015-08-11 | 2019-12-12 | 우시 바이올로직스 (케이만) 인코포레이티드 | 신규한 항-pd-1 항체 |
| WO2017210473A1 (en) | 2016-06-02 | 2017-12-07 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
| JP2021510697A (ja) * | 2018-01-12 | 2021-04-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | がん処置のための坑ｉｌ−８抗体及び坑ｐｄ−１抗体を用いる組合せ治療 |
| EP3752193A4 (en) * | 2018-02-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | METHODS OF TREATING CANCER WITH ANTI PD-1 ANTIBODIES AND ANTI CTLA4 ANTIBODIES |
| WO2020135415A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| KR20210146348A (ko) * | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| JP4896327B2 (ja) | 1999-08-23 | 2012-03-14 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｐｄ−１、ｂ７−４の受容体、およびその使用 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
| ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| US20060032289A1 (en) | 2004-08-11 | 2006-02-16 | Pinnaduwage Lal A | Non-optical explosive sensor based on two-track piezoresistive microcantilever |
| SI2439273T1 (sl) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
| CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1（pd-l1）的人单克隆抗体 |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| PE20110435A1 (es) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | Composiciones antagonistas del pd-1 |
| UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
| ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| CN103476943A (zh) | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | 用于增强治疗癌症的局部和全身性免疫调节疗法的组合 |
| DK2699264T3 (da) | 2011-04-20 | 2018-06-25 | Medimmune Llc | Antistoffer og andre molekyler, der binder b7-h1 og pd-1 |
| DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
| JP6448533B2 (ja) | 2012-05-15 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｐｄ−１／ｐｄ−ｌ１シグナル伝達を破壊することによる癌免疫療法 |
| CN109513003A (zh) * | 2012-08-14 | 2019-03-26 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
| SG11201508528TA (en) | 2013-05-02 | 2015-11-27 | Anaptysbio Inc | Antibodies directed against programmed death-1 (pd-1) |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| PL3702373T3 (pl) | 2013-09-13 | 2022-12-05 | Beigene Switzerland Gmbh | Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
-
2017
- 2017-06-01 EP EP23174335.2A patent/EP4248990A3/en active Pending
- 2017-06-01 FI FIEP17730627.1T patent/FI3463457T3/fi active
- 2017-06-01 CN CN201780047962.4A patent/CN109475633A/zh active Pending
- 2017-06-01 ES ES17730627T patent/ES2954139T3/es active Active
- 2017-06-01 RS RS20230598A patent/RS64388B1/sr unknown
- 2017-06-01 LT LTEPPCT/US2017/035492T patent/LT3463457T/lt unknown
- 2017-06-01 DK DK17730627.1T patent/DK3463457T3/da active
- 2017-06-01 HU HUE17730627A patent/HUE062398T2/hu unknown
- 2017-06-01 EP EP17730627.1A patent/EP3463457B1/en active Active
- 2017-06-01 JP JP2018563008A patent/JP7175198B2/ja active Active
- 2017-06-01 US US16/306,285 patent/US11083790B2/en active Active
- 2017-06-01 KR KR1020237008131A patent/KR20230038318A/ko not_active Application Discontinuation
- 2017-06-01 PT PT177306271T patent/PT3463457T/pt unknown
- 2017-06-01 HR HRP20230864TT patent/HRP20230864T1/hr unknown
- 2017-06-01 PL PL17730627.1T patent/PL3463457T3/pl unknown
- 2017-06-01 SI SI201731382T patent/SI3463457T1/sl unknown
- 2017-06-01 KR KR1020187037835A patent/KR20190015377A/ko active Application Filing
- 2017-06-01 WO PCT/US2017/035492 patent/WO2017210453A1/en unknown
-
2021
- 2021-08-09 US US17/397,221 patent/US20220025049A1/en active Pending
-
2022
- 2022-11-08 JP JP2022178836A patent/JP2023025012A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE062398T2 (hu) | 2023-10-28 |
| CN109475633A (zh) | 2019-03-15 |
| EP3463457B1 (en) | 2023-06-28 |
| JP7175198B2 (ja) | 2022-11-18 |
| EP4248990A2 (en) | 2023-09-27 |
| RS64388B1 (sr) | 2023-08-31 |
| PL3463457T3 (pl) | 2023-08-21 |
| JP2023025012A (ja) | 2023-02-21 |
| EP3463457A1 (en) | 2019-04-10 |
| SI3463457T1 (sl) | 2023-09-29 |
| KR20230038318A (ko) | 2023-03-17 |
| WO2017210453A1 (en) | 2017-12-07 |
| PT3463457T (pt) | 2023-09-07 |
| US20190290757A1 (en) | 2019-09-26 |
| FI3463457T3 (fi) | 2023-09-12 |
| US20220025049A1 (en) | 2022-01-27 |
| ES2954139T3 (es) | 2023-11-20 |
| LT3463457T (lt) | 2023-09-11 |
| JP2019517504A (ja) | 2019-06-24 |
| EP4248990A3 (en) | 2024-01-03 |
| HRP20230864T1 (hr) | 2023-11-10 |
| US11083790B2 (en) | 2021-08-10 |
| KR20190015377A (ko) | 2019-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3463457T3 (da) | Pd-1-blokade med nivolumab ved refraktært hodgkins lymfom | |
| IL259987A (en) | Antibody molecules against pd-1 and their uses | |
| DK3356401T3 (da) | Bindingsmolekyler med modificeret j-kæde | |
| SMT201600470B (it) | Inibitori del virus dell'epatite c | |
| DK2947246T3 (da) | Snap-in-hængsel med dæmpet lukning | |
| BR112016026251A2 (pt) | processo de polimerização em lama para formar polietileno | |
| FR3052789B1 (fr) | Composition d'acier | |
| GB2550703B (en) | Crosslinked polymer compositions with two crosslinkers for use in subterranean formation operations | |
| DK3448416T3 (da) | Semaglutid ved kardiovaskulære tilstande | |
| MA40911A (fr) | Compositions de piégeage d'oxygène ne nécessitant pas de période d'induction | |
| DK3371126T3 (da) | Manipuleret hybrid cementbaseret sammensætning med øget modstandsdygtighed over for befugtning | |
| DK3134483T3 (da) | Vandig sammensætning med forbedret brudforlængelse | |
| HK1251595A1 (zh) | 用於光學製品的組合物及用其製造的光學製品 | |
| DK3236811T3 (da) | Beskyttelsesartikler | |
| EP3000121A4 (en) | PHOTOCURABLE COMPOSITION AND METHODS FOR OPTICAL COMPONENT USING THE SAME | |
| DK3423082T5 (da) | Liraglutid ved kardiovaskulære tilstande | |
| HK1217918A1 (zh) | 用於治療何杰金氏淋巴瘤的 -氰基- -二甲基環己- -烯- -基 -四甲基四氫- -吡喃- -基 吡啶- -基 -咪唑- -酰胺 | |
| FR3037944B1 (fr) | Materiau nanostructure de bore amorphe | |
| FR3045538B1 (fr) | Moto-reducteur d'essuie-glace | |
| BR112016029865A2 (pt) | liga ferrosa | |
| GB2570610B (en) | Improvements in or relating to area denial | |
| ITUB20152671A1 (it) | Risparmiatore elettrico al 100 x 100 | |
| GB201617838D0 (en) | Improvements in or relating to area denial | |
| DK3219236T3 (da) | Holdeplade med forbedret lukning | |
| ITRM20150015U1 (it) | "marciapiede multimadiale" |